GlassScriptPhysician profile
Meghan Nahass
NPI 1649627951
$18,875.51
in general payments reported to CMS, 2019-2025
16 companies · $17K in 2025
The $17K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $241 · 2021: $666 · 2022: $297 · 2023: $460 · 2024: $133 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Food and Beverage: $1,108 · Travel and Lodging: $347 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $292.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,925.00 |
| Food and Beverage | $1,108.08 |
| Travel and Lodging | $346.61 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $292.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11,245.48 | 2020-2025 | |
| Bridgebio Pharma, INC. | $5,727.21 | 2025 | Attruby |
| Astrazeneca Pharmaceuticals LP | $421.87 | 2021-2025 | Farxiga |
| Astellas Pharma US INC | $297.00 | 2020-2022 | |
| Abbott Laboratories | $239.23 | 2021-2023 | Optis, Thoratec Heartmate 3 Lvas Implant Kit |
| Novartis Pharmaceuticals Corporation | $197.71 | 2023-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.50 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $133.14 | 2021-2025 | Lifevest |
| Abiomed | $126.49 | 2023 | Impella |
| Janssen Pharmaceuticals, INC | $113.18 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $91.91 | 2021-2023 | Camzyos |
| Shockwave Medical, INC | $50.98 | 2021 | |
| Amgen INC. | $48.36 | 2024-2025 | Repatha, Repatha |
| Heartflow, INC. | $23.40 | 2025 | |
| Alnylam Pharmaceuticals INC. | $21.05 | 2025 | Onpattro |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meghan Nahass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.